Unfortunately, we found that TCF1 and BCL11B expression was decreased in CLL patients, and this resulted in impaired differentiation potential for effector CD8+ T cells (21, 22), which clinically manifested as the accumulation of terminally differentiated T cells (44), immune function dysfunction, and further rapid CLL progression. Here, BCL11B is linked to B-cell chronic lymphocytic leukemia.